- Affiliate Assistant Professor, Global Health
Select from the following:
Mark Orr, Ph.D. is an immunologist in the Pre-Clinical Biology group. As a Senior Scientist and Principal Investigator at IDRI his research interests include:
Developing novel adjuvanted vaccines for bacterial diseases including tuberculosis and ETEC that have a major impact on global health.
The cellular and molecular mechanisms of adjuvant activity.
Immunologic characterization and development of new vaccine adjuvants.
Mark is also an Affiliate Assistant Professor in the University of Washington, Department of Global Health Interdisciplinary Pathobiology Program. He has published over 25 peer-reviewed articles in the fields of immunology and vaccine development. He is a member of the American Association of Immunologists and serves on the editorial board of Frontiers in NK Cell Biology.
Mark received his Ph.D. from the Department of Immunology at the University of Washington. His thesis work with Dr. Chris Wilson was focused on the immune evasion strategies employed by herpes simplex virus. Mark did his postdoctoral work with Dr. Lewis Lanier at the University of California, San Francisco, where he researched the response of natural killer (NK) cells to viral infection, studying both the signaling pathways and educational programs that shape NK cell responses to infection in vivo.
- PhD, University of Washington
- BS, Tennessee Technological University
- Drug and Vaccine Development
- Immunizations
- Infectious Diseases
IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.
Desbien AL, Dubois Cauwelaert N, Reed SJ, Bailor HR, Liang H, Carter D, Duthie MS, Fox CB, Reed SG, Orr MT.
J Immunol. 2016 Dec 1;197(11):4351-4359. Epub 2016 Oct 28.
PMID: 27794001
The science of vaccine adjuvants: advances in TLR4 ligand adjuvants.
Reed SG, Hsu FC, Carter D, Orr MT.
Curr Opin Immunol. 2016 Aug;41:85-90. doi: 10.1016/j.coi.2016.06.007. Epub 2016 Jul 5. Review.
PMID: 27392183
The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction.
Dubois Cauwelaert N, Desbien AL, Hudson TE, Pine SO, Reed SG, Coler RN, Orr MT.
PLoS One. 2016 Jan 5;11(1):e0146372. doi: 10.1371/journal.pone.0146372. eCollection 2016.
PMID: 26731269
Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.
Orr MT, Beebe EA, Hudson TE, Argilla D, Huang PW, Reese VA, Fox CB, Reed SG, Coler RN.
Vaccine. 2015 Nov 27;33(48):6570-8. doi: 10.1016/j.vaccine.2015.10.115. Epub 2015 Nov 3.
PMID: 26541135
Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism.
Coler RN, Hudson T, Hughes S, Huang PW, Beebe EA, Orr MT.
J Immunol. 2015 Oct 1;195(7):3190-7. doi: 10.4049/jimmunol.1501118. Epub 2015 Aug 21.
PMID: 26297758